Vellenga 1996.

Study characteristics
Methods	Placebo‐controlled, public‐ and industry‐funded, multicenter trial
Participants	Adults; mixed tumors; ANC < 0.5 x 109/L
Interventions	GM‐CSF (Sandoz) 5 mcg/kg SC ATB: Imipenem, cefuroxime in combination with an aminoglycoside, Augmentin in combination with an aminoglycoside, and Ceftazidime
Outcomes	Overall mortality Infection‐related mortality Duration of hospitalization Deep vein thrombosis Bone and joint pain or flu‐like symptoms
Notes	Hospital discharge criteria: afebrile for at least 72 hours; ANC at least 1000/mm3 Duration of grade IV neutropenia reported as median number of days of neutropenia ANC < 0.5 x 109/L
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Description of method of sequence generation is not provided
Allocation concealment (selection bias)	Unclear risk	Description of method of allocation concealment is not provided
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blinding was employed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	We were not able to assess who were blinded based on the information provided in the article
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We were not able to assess the outcomes for which blinding was employed based on the information provided in the article
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis used, withdrawals are described
Other bias	Low risk	Prespecified values of sample size, alpha and beta errors were provided